NEUBASE THERAPEUTICS INC (NBSE) Stock Price, Forecast & Analysis
USA - NASDAQ:NBSE - US64132K2015 - Common Stock
NBSE Key Statistics, Chart & Performance
The current stock price of NBSE is 0.378 USD. In the past month the price decreased by -13.84%. In the past year, price decreased by -90.27%.
NBSE Latest News, Press Relases and Analysis
NBSE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.49 | 375.40B | ||
| AMGN | AMGEN INC | 13.55 | 159.12B | ||
| GILD | GILEAD SCIENCES INC | 14.81 | 150.51B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.05 | 108.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.22 | 67.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 844.2 | 56.44B | ||
| ARGX | ARGENX SE - ADR | 61.51 | 50.79B | ||
| INSM | INSMED INC | N/A | 39.36B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.03 | 34.25B | ||
| NTRA | NATERA INC | N/A | 27.09B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.97B | ||
| BIIB | BIOGEN INC | 9.08 | 22.29B |
Related stock screener links
About NBSE
Company Profile
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania. The company went IPO on 2014-05-28. The company is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company’s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. The company uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntington’s disease (HD), and oncology and in gene editing applications. The company also focused on identifying and evaluating multiple indications for potential development.
Company Info
NEUBASE THERAPEUTICS INC
350 Technology Drive
Pittsburgh PENNSYLVANIA 15219 US
CEO: Dietrich Stephan
Employees: 37
Phone: 14127633350
NEUBASE THERAPEUTICS INC / NBSE FAQ
What does NEUBASE THERAPEUTICS INC do?
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania. The company went IPO on 2014-05-28. The company is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company’s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. The company uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntington’s disease (HD), and oncology and in gene editing applications. The company also focused on identifying and evaluating multiple indications for potential development.
What is the current price of NBSE stock?
The current stock price of NBSE is 0.378 USD. The price decreased by -3.2% in the last trading session.
What is the dividend status of NEUBASE THERAPEUTICS INC?
NBSE does not pay a dividend.
What is the ChartMill technical and fundamental rating of NBSE stock?
NBSE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting NBSE stock to perform?
6 analysts have analysed NBSE and the average price target is 142.8 USD. This implies a price increase of 37677.78% is expected in the next year compared to the current price of 0.378.
Is NEUBASE THERAPEUTICS INC (NBSE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NBSE.
What is NEUBASE THERAPEUTICS INC worth?
NEUBASE THERAPEUTICS INC (NBSE) has a market capitalization of 1.42M USD. This makes NBSE a Nano Cap stock.
NBSE Technical Analysis
NBSE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NBSE. The financial health of NBSE is average, but there are quite some concerns on its profitability.
NBSE Financial Highlights
Over the last trailing twelve months NBSE reported a non-GAAP Earnings per Share(EPS) of -7.3. The EPS increased by 55.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.74% | ||
| ROE | -150.22% | ||
| Debt/Equity | 0 |
NBSE Forecast & Estimates
6 analysts have analysed NBSE and the average price target is 142.8 USD. This implies a price increase of 37677.78% is expected in the next year compared to the current price of 0.378.